María Hernández-Sánchez

Profesor Ayudante Doctor

Universidad Complutense de Madrid Facultad de Medicina

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

María Hernández-Sánchez is a Profesor Ayudante Doctor at Universidad Complutense de Madrid Facultad de Farmacia in Spain. Her research focuses on hematological malignancies, particularly chronic lymphocytic leukemia (CLL), with recent articles exploring B-cell development, gene mutations, and therapeutic vulnerabilities. She employs advanced methodologies including CRISPR screenings and in vivo modeling to investigate the biological significance of genetic alterations in hematological neoplasms.

Articles (11)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (9)

Jesús María Hernández-Rivas

Universidad de Salamanca

SPAIN

View details

Ana Herrero

Universidad de Salamanca

SPAIN

View details

Shanye Yin

Assistant Professor

Albert Einstein College of Medicine

UNITED STATES

View details

Kendell Clement

Assistant Professor

University of Utah

UNITED STATES

View details

Ana‐Eugenia Rodríguez‐Vicente

Universidad de Salamanca

SPAIN

View details

Maria Linares

Assistant PhD Professor

Universidad Complutense de Madrid

SPAIN

View details

Professor Jonathan C Strefford

Professor of Molecular Oncology

University of Southampton

UNITED KINGDOM

View details

Sébastien Hergalant

INSERM

FRANCE

View details

Lars Bullinger

Charité University Medicine

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

María Hernández-Sánchez

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches

Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models

A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions

In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

High-Throughput CRISPR Screening in Hematological Neoplasms

TRAF3 alterations are frequent in del‐3′IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features

CRISPR/Cas9 in Chronic Lymphocytic Leukemia

Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia

Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression

From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct

Collaborators (9)

Jesús María Hernández-Rivas

Ana Herrero

Shanye Yin

Kendell Clement

Ana‐Eugenia Rodríguez‐Vicente

Maria Linares

Professor Jonathan C Strefford

Sébastien Hergalant

Lars Bullinger

Make your next move.